Try
Syndax Pharmaceuticals Inc
SNDXUnited States
43 filed reports · 404 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
43 reports · Mar 2016 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 32 | 3,496 | Mar 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 3,530 | Dec 2016 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2020 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 338 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 196 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 710 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 3, 2025 | 217 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 4, 2025 | 127 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 5, 2025 | 125 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 3, 2025 | 362 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 5, 2024 | 118 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 93 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 93 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 27, 2024 | 312 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 116 | Open |
Financial data
404 concepts · 7,027 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial388 concepts · 6,817 facts · Dec 2014 to Jul 2026
- Cash and cash equivalents at carrying value59 · Dec 2014 to Jun 2026
- Allocated share based compensation expense58 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable58 · Dec 2014 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities58 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Net income loss available to common stockholders basic58 · Dec 2014 to Jun 2026
- Nonoperating income expense58 · Dec 2014 to Jun 2026
- Operating expenses (US GAAP)58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Other nonoperating income expense58 · Dec 2014 to Jun 2026
- Payments to acquire short term investments58 · Dec 2014 to Jun 2026
- Proceeds from sale and maturity of available for sale securities58 · Dec 2014 to Jun 2026
- Research and development expense58 · Dec 2014 to Jun 2026
- Share based compensation58 · Dec 2014 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax57 · Mar 2015 to Jun 2026
- Stockholders equity (US GAAP)56 · Dec 2014 to Jun 2026
- Common stock par or stated value per share55 · Dec 2015 to Jun 2026
- Accounts payable current54 · Dec 2015 to Jun 2026
- Accrued liabilities and other liabilities54 · Dec 2015 to Jun 2026
- Assets54 · Dec 2015 to Jun 2026
- Assets current54 · Dec 2015 to Jun 2026
- Available for sale debt securities amortized cost basis54 · Dec 2015 to Jun 2026
- Available for sale securities debt securities54 · Dec 2015 to Jun 2026
Segment13 concepts · 172 facts · Dec 2022 to Jun 2026
- Research and development expense28 · Dec 2022 to Jun 2026
- Biopharmaceutical Cancer Therapeutics14 · Dec 2022 to Jun 2026
- Cost of product sales14 · Dec 2022 to Jun 2026
- Interest income expense net14 · Dec 2022 to Jun 2026
- Marketing and advertising expense14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Other general and administrative expense14 · Dec 2022 to Jun 2026
- Other operating income expense net14 · Dec 2022 to Jun 2026
- Other research and development expense14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Royalty expense13 · Dec 2023 to Jun 2026
- Incyte Agreement3 · Mar 2024 to Mar 2026
- Convertible note interest expense2 · Jun 2025 to Jun 2026
Product1 concepts · 33 facts · Dec 2022 to Jun 2026
- Revenue33 · Dec 2022 to Jun 2026
Geography2 concepts · 5 facts · Dec 2016 to Dec 2025
- Income taxes paid net4 · Dec 2025
- Operating leases rent expense minimum rentals1 · Dec 2016
Segments
210 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 172 facts
- Biopharmaceutical Cancer Therapeutics172 · Dec 2022 to Jun 2026
Product or service4 members · 33 facts
- Collaboration Revenue12 · Dec 2023 to Jun 2026
- Milestone Revenue10 · Dec 2022 to Dec 2025
- Product7 · Jun 2024 to Jun 2026
- Net Product Revenues4 · Dec 2022 to Dec 2025
Statement geographicalsrt:StatementGeographicalAxis4 members · 4 facts
- MA1 · Dec 2025
- NY1 · Dec 2025
- Other Country1 · Dec 2025
- TN1 · Dec 2025
Statement geographicalus-gaap:StatementGeographicalAxis1 member · 1 facts
- MA1 · Dec 2016
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.